marked.bio

anti-EGFR antibody · antibody

necitumumab

2 active trials across 3 of our biomarkers, targeting EGFR. Not approved for any biomarker on marked.bio yet.

Also known as IMC-11F8, Portrazza.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
EGFR exon 19 deletion / L858R 2 6 Phase 1/2
EGFR exon 20 insertion 1 1 Phase 1
ALK fusion 0 2 –

Trials

2 of 6 trials shown

  1. Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

    Active, not recruiting Phase 1/2 Jonsson Comprehensive Cancer Center Started 2021Primary completion 2026-12 NCT04285671

    necitumumabosimertinib FDA EUtrastuzumab

    Enrollment of patients with mutations other than exon 19 deletion and the L858R point mutation require literature supporting sensitivity to EGFR tyrosine k…

    EGFR exon 19 deletion / L858RMetastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Lung Cancer AJCC v8

  2. Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

    Active, not recruiting Phase 1 National Cancer Institute (NCI) Started 2016Primary completion 2027-06 NCT02496663

    necitumumabosimertinib FDA EU

    NSCLC must harbor at least one of the following EGFR activating mutations: Exon 21 L858R, Exon 19 deletion, Exon 18 G719X, Exon 21 L861Q or for EGFR Exon 20 insertion expansion cohort D, NSCLC mus…

    EGFR exon 19 deletion / L858REGFR exon 20 insertionMetastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8